Conen, Patrick
Pennetta, Francesca
Dendl, Katharina
Hertel, Fabian
Vogg, Andreas
Haberkorn, Uwe
Giesel, Frederik L.
Mottaghy, Felix M. http://orcid.org/0000-0002-7212-6521
Funding for this research was provided by:
Universitätsklinikum RWTH Aachen
Article History
Received: 30 September 2021
Accepted: 12 December 2021
First Online: 6 January 2022
Change Date: 28 April 2022
Change Type: Update
Change Details: The article was modified to add the missing funding note.
Declarations
:
: Retrospective data analysis was approved by the Ethics Committee of the University Hospital Heidelberg (permit S016/2018) und the University Hospital RWTH Aachen (CTCA number 20–569).
: Informed consent was obtained from all individual participants included in the study.
: Patients signed informed consent regarding publishing their data and photographs.
: UH, AL, TL WM, CK, and FLG have a patent application for quinolone based FAP-targeting agents for imaging and therapy in nuclear medicine. UH, and FLG also have shares of a consultancy-group for iTheranostics. FLG is medical advisor for ABX advanced biochemical compound, Sofie Biosciences and Telix Pharmaceuticals. FMM is medical advisor for NanoMab Technology Ltd. and Advanced Accelerator Applications (AAA) GmbH and has recently received institutional grants from NanoMab Technology Ltd., Siemens and GE Precision Healthcare LLC.